Profile data is unavailable for this security.
About the company
Procter & Gamble Health Limited is an India-based multinational consumer goods company. The Company is focused on manufacturing and marketing of over-the-counter products, vitamins, minerals, and supplements products for a healthy lifestyle. The Company is engaged in the manufacturing and selling of healthcare products, such as vitamins, minerals and supplements. Patients are end consumers of the products. The Company’s distribution channels (direct and indirect), inter alia, include distributors, health care professionals, pharmacies and chemists. The Company’s brands include Polybion, Cosome, Evion, Neurobion, Seven Seas, Nasivion, and Livogen. Cosome is a medicine which is used to help relieve dry coughs and related congestion symptoms. Evion is a Vitamin E capsules. The Seven Seas is a pure vitamin rich cod-liver oil. Neurobion offers a range of neurotropic supplements. Its products are sold in about 180 countries and territories throughout the world.
- Revenue in INR (TTM)11.60bn
- Net income in INR2.18bn
- Incorporated1967
- Employees1.34k
- LocationProcter & Gamble Health LtdGodrej One,8Th Floor Pirojshanagar, Vikhroli (East)MUMBAI 400079IndiaIND
- Phone+91 2 262109000
- Fax+91 2 262109999
- Websitehttps://www.pghealthindia.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Solara Active Pharma Sciences Ltd | 12.22bn | -5.36bn | 43.38bn | 2.16k | -- | 2.60 | -- | 3.55 | -137.13 | -137.13 | 320.29 | 301.63 | 0.4731 | 1.77 | 2.69 | 5,667,023.00 | -20.76 | -2.44 | -36.40 | -3.84 | 38.70 | 41.16 | -43.89 | -4.49 | 0.448 | -1.30 | 0.4355 | -- | -10.73 | -1.45 | -2,458.12 | -- | -4.81 | -- |
| Hikal Ltd | 18.21bn | 735.12m | 48.80bn | 2.06k | 66.46 | 4.05 | 24.60 | 2.68 | 5.95 | 5.95 | 147.30 | 97.60 | 0.7509 | 2.37 | 4.27 | 8,837,312.00 | 3.03 | 5.07 | 4.26 | 7.51 | 54.14 | 46.78 | 4.04 | 5.86 | 0.8421 | 2.46 | 0.3919 | 12.19 | -11.79 | 2.34 | -11.20 | -7.55 | 9.72 | 0.00 |
| Jeena Sikho Lifecare Ltd | -100.00bn | -100.00bn | 48.96bn | 1.23k | -- | 154.84 | -- | -- | -- | -- | -- | 12.72 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 0.8228 | -- | 0.2681 | -- | 43.84 | -- | 77.37 | -- | -- | -- |
| SeQuent Scientific Ltd | 14.49bn | 164.77m | 50.49bn | 1.20k | 309.79 | 7.44 | 54.51 | 3.48 | 0.6537 | 0.6537 | 57.25 | 27.23 | 0.9464 | 2.28 | 4.46 | 12,129,000.00 | 1.79 | 1.09 | 2.94 | 1.76 | 45.86 | 41.97 | 1.89 | 1.18 | 0.9564 | 1.26 | 0.3974 | 35.06 | -3.60 | 5.68 | 70.40 | -- | 6.96 | -- |
| Innova Captab Ltd | 11.78bn | 1.18bn | 57.50bn | -- | 40.12 | 6.42 | 42.12 | 4.88 | 25.04 | 25.04 | 232.86 | 156.45 | 0.903 | 4.83 | 3.74 | -- | 9.07 | 10.82 | 12.50 | 18.38 | 34.06 | 25.18 | 10.05 | 8.04 | 1.32 | 19.79 | 0.2259 | -- | 16.72 | 24.90 | 38.84 | 36.55 | 104.14 | -- |
| Aarti Pharmalabs Ltd | 19.68bn | 2.28bn | 57.62bn | 1.63k | 25.26 | 3.10 | 18.77 | 2.93 | 25.16 | 25.16 | 217.12 | 204.88 | 0.7733 | 1.62 | 4.59 | 12,095,750.00 | 8.96 | -- | 11.86 | -- | 45.56 | -- | 11.59 | -- | 0.9611 | 17.12 | 0.1723 | -- | -4.76 | -- | 12.10 | -- | -- | -- |
| Unichem Laboratories Ltd | 17.75bn | -55.72m | 60.13bn | 3.19k | -- | 2.50 | 56.56 | 3.39 | -0.7948 | -0.7948 | 251.56 | 340.97 | 0.5563 | 0.9064 | 2.85 | 5,556,270.00 | -0.1747 | -1.67 | -0.2226 | -2.03 | 62.33 | 56.18 | -0.314 | -3.99 | 1.20 | 2.77 | 0.1111 | -- | 26.94 | 7.64 | 65.15 | -- | -35.00 | -- |
| Supriya Lifescience Ltd | 6.25bn | 1.58bn | 63.84bn | 448.00 | 40.59 | 7.05 | 36.52 | 10.21 | 19.54 | 19.54 | 77.55 | 112.56 | 0.6737 | 2.01 | 6.56 | 13,950,510.00 | 16.98 | 19.08 | 18.38 | 24.04 | 66.81 | 57.12 | 25.20 | 24.71 | 4.05 | 111.46 | 0.006 | 2.88 | 23.74 | 15.47 | 32.56 | 24.75 | 83.79 | -- |
| Sun Pharma Advanced Research Co Ltd | 600.85m | -4.09bn | 65.62bn | 409.00 | -- | -- | -- | 109.21 | -12.60 | -12.60 | 1.85 | -2.38 | 0.1216 | -- | 2.66 | 1,469,078.00 | -82.71 | -61.70 | -164.56 | -119.31 | 51.18 | 74.49 | -680.16 | -163.40 | -- | -145.15 | 4.25 | -- | -68.36 | -16.21 | -73.96 | -- | 15.40 | -- |
| Orchid Pharma Ltd | 9.05bn | 1.20bn | 76.90bn | 872.00 | 63.29 | 6.28 | 50.20 | 8.50 | 23.96 | 23.96 | 181.23 | 241.38 | 0.5787 | 1.96 | 4.49 | 10,376,120.00 | 7.57 | -0.9734 | 9.09 | -1.40 | 41.26 | 40.74 | 13.09 | -2.40 | 1.82 | 6.74 | 0.1187 | -- | 23.05 | 6.43 | 73.59 | 5.84 | 57.79 | -- |
| F D C Ltd | 20.72bn | 3.17bn | 80.46bn | 6.66k | 25.53 | 3.51 | 22.24 | 3.88 | 19.36 | 19.36 | 126.27 | 140.76 | 0.824 | 2.16 | 12.48 | 3,112,058.00 | 12.59 | 12.05 | 14.46 | 13.73 | 65.35 | 61.54 | 15.27 | 15.85 | 2.49 | 72.53 | 0.0087 | 1.09 | 8.92 | 12.24 | 57.30 | 12.45 | 16.93 | -- |
| Procter & Gamble Health Ltd | 11.60bn | 2.18bn | 85.32bn | 1.34k | 39.20 | -- | 34.90 | 7.36 | 131.10 | 131.10 | 698.14 | -- | -- | -- | -- | 8,680,689.00 | -- | -- | -- | -- | 71.42 | -- | 18.77 | -- | -- | 441.58 | -- | -- | -6.37 | -- | -12.42 | -- | -- | -- |
| Shilpa Medicare Ltd | 12.15bn | 610.83m | 87.74bn | 931.00 | 134.61 | 3.77 | 51.63 | 7.22 | 6.67 | 6.67 | 132.68 | 238.05 | 0.3969 | 1.24 | 3.40 | 13,047,900.00 | 2.00 | 2.84 | 2.44 | 3.65 | 66.38 | 60.08 | 5.04 | 7.03 | 1.08 | 1.79 | 0.1746 | 10.76 | 9.66 | 9.44 | 198.15 | -22.26 | -9.26 | -- |
| Blue Jet Healthcare Ltd | 7.22bn | 1.68bn | 91.62bn | 447.00 | 54.58 | 9.92 | 47.83 | 12.69 | 9.68 | 9.68 | 41.61 | 53.27 | 0.6732 | 1.97 | 3.46 | 16,149,080.00 | 15.66 | -- | 19.57 | -- | 55.65 | -- | 23.26 | -- | 2.51 | 131.95 | 0.0012 | -- | -1.30 | -- | 2.33 | -- | -- | -- |
| Akums Drugs and Pharmaceuticals Ltd | 40.79bn | 2.78bn | 105.78bn | 7.39k | 36.80 | 3.63 | 25.32 | 2.59 | 18.26 | 18.26 | 272.23 | 185.07 | 1.04 | 3.77 | 3.94 | 5,521,446.00 | 7.20 | -- | 11.08 | -- | 37.76 | -- | 6.95 | -- | 1.59 | 2.23 | 0.1571 | -- | 14.32 | -- | -104.25 | -- | -- | -- |
| Sanofi Consumer Healthcare India Ltd | -100.00bn | -100.00bn | 110.30bn | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
Data as of Nov 26 2024. Currency figures normalised to Procter & Gamble Health Ltd's reporting currency: Indian Rupee INR
17.21%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Nippon Life India Asset Management Ltd. (Invt Mgmt)as of 30 Sep 2023 | 596.81k | 3.60% |
| ICICI Prudential Asset Management Co. Ltd.as of 31 Oct 2024 | 436.41k | 2.63% |
| Life Insurance Corporation of India (Investment Portfolio)as of 30 Sep 2023 | 399.97k | 2.41% |
| HDFC Asset Management Co. Ltd. (Invt Mgmt)as of 30 Sep 2023 | 338.85k | 2.04% |
| UTI Asset Management Co. Ltd. (Investment Management)as of 31 Oct 2024 | 314.38k | 1.89% |
| The Vanguard Group, Inc.as of 06 Nov 2024 | 275.09k | 1.66% |
| DSP Asset Managers Pvt. Ltd.as of 31 Oct 2024 | 158.70k | 0.96% |
| Dimensional Fund Advisors LPas of 07 Nov 2024 | 130.99k | 0.79% |
| BlackRock Fund Advisorsas of 07 Nov 2024 | 118.64k | 0.72% |
| Sundaram Asset Management Co. Ltd.as of 31 Oct 2024 | 86.31k | 0.52% |
More ▼
Data from 30 Sep 2024 - 21 Nov 2024Source: FactSet Research Systems Inc.
